There is on-going development of generic EU CTD Dossier of Valsartan and Valsartan+HCTZ, tablets.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Valsartan is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT1 receptor subtype.
More detais at http://www.rxlist.com/cgi/generic/valsartan.htm
|Pharma licensing||Out-licensing (offer)|